Dublin, Ireland, May 12th, 2020 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer, today announced that it will participate in three upcoming virtual investor and partnering conferences:
· Sachs Associates 6th Annual Digital Immuno-Oncology Innovation Forum, May 26-27, 2020
· Digital RESI Three Day Conference, June 8-10, 2020
· BIO Digital, June 8-12, 2020
Members of the management team will be available for virtual meetings throughout the three conferences. To arrange a meeting please contact business development at bd@inflectionbio.com or visit the 6th Annual Digital Immuno-Oncology Innovation Forum webpage, the Digital RESI webpage or the BIO One-on-One Partnering webpage to schedule a meeting directly.
About Sachs Associates 6th Digital Immuno-Oncology Innovation Forum
The Sachs Associates Digital Immuno-Oncology Innovation Forum brings together, virtually, leaders from cancer research institutes, patient advocacy groups, early- and late-stage investors, pharma and biotech companies. The programme will cover licensing and investment opportunities in the immuno-oncology field.
About Life Science Nation’s Digital RESI Conference
The Redefining Early Stage Investments (RESI) conference series was created by Life Science Nation (LSN) to bring together start-ups with early-stage investors and strategic channel partners. The goal was to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. What is unique about RESI is that the event is cross border and cross domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics, and digital health, the “4 Ds”. RESI caters to both the earliest stage startups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding.
About BIO Digital
For 2020, the BIO International Convention will transition to a new, virtual event format, BIO Digital. This virtual gathering of the global biotech industry provides access to key partners via BIO One-on-One Partnering, educational resources, and the insights to continue critical research and development.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline includes the first-in-class IBL-202, a dual PIM kinase and PI3K inhibitor in development for B-cell malignancies and the IBL-100s, selective pan-PIM kinase inhibitors. The partnered pipeline comprises AUM302, being developed by AUM Biosciences. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com
For Further Information Contact:
Inflection Biosciences Ltd
Darren Cunningham, Chief Executive Officer
E: dcunningham@inflectionbio.com
T: +353 (0)1 4003615